Genetic Technologies (Australia) Performance
| GTG Stock | 0.04 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.89, which attests to possible diversification benefits within a given portfolio. Genetic Technologies returns are very sensitive to returns on the market. As the market goes up or down, Genetic Technologies is expected to follow. At this point, Genetic Technologies has a negative expected return of -0.14%. Please make sure to check out Genetic Technologies' maximum drawdown, potential upside, and the relationship between the jensen alpha and value at risk , to decide if Genetic Technologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genetic Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's technical and fundamental indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Last Split Factor 1:100 | Last Split Date 2023-12-14 |
1 | Genetic Technologies Embraces Capital-Light Model - TipRanks | 08/29/2024 |
2 | Genetic Technologies Enters Voluntary Administration - TipRanks | 11/19/2024 |
| Begin Period Cash Flow | 7.9 M |
Genetic |
Genetic Technologies Relative Risk vs. Return Landscape
If you would invest 4.30 in Genetic Technologies on September 3, 2024 and sell it today you would lose (0.40) from holding Genetic Technologies or give up 9.3% of portfolio value over 90 days. Genetic Technologies is producing return of less than zero assuming 3.7474% volatility of returns over the 90 days investment horizon. Simply put, 33% of all stocks have less volatile historical return distribution than Genetic Technologies, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Genetic Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genetic Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genetic Technologies, and traders can use it to determine the average amount a Genetic Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0382
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GTG |
Estimated Market Risk
| 3.75 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genetic Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genetic Technologies by adding Genetic Technologies to a well-diversified portfolio.
Genetic Technologies Fundamentals Growth
Genetic Stock prices reflect investors' perceptions of the future prospects and financial health of Genetic Technologies, and Genetic Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genetic Stock performance.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 5.53 M | ||||
| Shares Outstanding | 145.42 M | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.66 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (12.02 M) | ||||
| Total Debt | 875.19 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Total Asset | 6.19 M | ||||
| Retained Earnings | (166.38 M) | ||||
About Genetic Technologies Performance
Assessing Genetic Technologies' fundamental ratios provides investors with valuable insights into Genetic Technologies' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Genetic Technologies is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Genetic Technologies is entity of Australia. It is traded as Stock on AU exchange.Things to note about Genetic Technologies performance evaluation
Checking the ongoing alerts about Genetic Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genetic Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genetic Technologies generated a negative expected return over the last 90 days | |
| Genetic Technologies has some characteristics of a very speculative penny stock | |
| Genetic Technologies has high historical volatility and very poor performance | |
| Genetic Technologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 7.66 M. Net Loss for the year was (12.02 M) with profit before overhead, payroll, taxes, and interest of 6.01 M. | |
| Genetic Technologies generates negative cash flow from operations | |
| Latest headline from news.google.com: Genetic Technologies Enters Voluntary Administration - TipRanks |
- Analyzing Genetic Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genetic Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Genetic Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genetic Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genetic Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genetic Technologies' stock. These opinions can provide insight into Genetic Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.